PET/CT in primary musculoskeletal tumours: a step forward.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 20577880.
- Also identified by DOI 10.1007/s00330-010-1862-z.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Hybrid imaging with combined positron emission tomography/computed tomography (PET/CT) plays an important role in the staging and management of a wide variety of solid tumours. However, its use in the evaluation of musculoskeletal malignancy has not yet entered routine clinical practice. Cross-sectional imaging with magnetic resonance imaging (MR) and computed tomography have well-established roles but there is increasing evidence for the selective use of PET/CT in the management of these patients. The aims of this article are to review the current evidence and clinical applications of PET/CT in primary musculoskeletal tumours and discuss potential future developments using novel PET tracers and integrated PET/MR.
Medical subject headings
- Bone Neoplasms
- Fluorodeoxyglucose F18
- Muscle Neoplasms
- Positron-Emission Tomography
- Subtraction Technique
- Tomography, X-Ray Computed